ASweetLife Team, Author at ASweetLife

Victoza Improves Blood Sugar Control in Patients with Type 2 Diabetes

According to a Novo Nordisk announcement the results from their LEAD™ 6 extension study show that switching to once-daily Victoza® (Liraglutide [rDNA Origin] Injection) from exenatide improves blood sugar control in patients with type 2 diabetes. The study published online in Diabetes Care evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza...

Novo Nordisk Launches New Resource for Information on Diabetes

Novo Nordisk announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care. The first issue of the Novo Nordisk BlueSheet examines how legislation, advocacy and research can help change the way diabetes is funded and treated in the U.S. today....

Lunch Time Coffee Reduces Type 2 Diabetes Risk

Many studies have shown that drinking coffee, regular or decaf, with or without sugar, reduces the risk of developing type 2 diabetes. A new study, reported by the Globe and Mail has found that when you drink your coffee may have an effect on diabetes risk...

Passover Food

Passover food isn't low-carb. If you're going to a Seder this year, there is likely to be more than enough matzo to go around. Matzo, a bread substitute, has over 20 grams of carbohydrate per slice. Our advice - have a bite or two and then move right on to the gefilte fish.

Leptin Therapy as a Treatment for Type 1 Diabetes

Leptin, a hormone discovered in 1994 by Rudolph L. Leibel, is produced by fat cells. Leptin plays an important role in regulating appetite and in glucose and fat metabolism. Its discovery pioneered the concept that adipose tissue is not a silent energy-storage organ, but actually an active endocrine organ...

JDRF Funded Researchers Test Topical Drug to Treat Diabetic Macular Edema

The Juvenile Diabetes Research Foundation (JDRF) announced that researchers at the Wilmer Eye Institute of Johns Hopkins University School of Medicine in Maryland completed a multicenter human clinical trial treating diabetic macular edema with mecamylamine, a topical drug developed by the biotech company CoMentis, Inc. Funding for the study was provided by JDRF through its Industry Drug Development Partnership program...

Diabetes At Epidemic Proportions in China

According to a new study published in the The New England Journal of Medicine, 92.4 million Chinese adults age 20 or older (9.7 percent of the population) have diabetes and 148.2 million more (15.5 percent) have prediabetes. Researchers from Tulane University administered an oral glucose tolerance test to 46,239 adults aged 20 or older from 14 provinces...

FDA Grants Diamyd Medical´s Diamyd Orphan Drug Designation

Diamyd Medical announced the Food and Drug Administration (FDA) granted its type 1 diabetes drug candidate Diamyd® Orphan Drug Designation. Orphan drugs qualify for several incentives including a seven-year period of market exclusivity in the US...

Preventable Risk Factors Reduce Life Expectancy in US

A new study, published online by PLoS Medicine, estimates that smoking, high blood pressure, elevated blood glucose, and obesity currently reduce life expectancy in the U.S. by 4.9 years in men and 4.1 years in women. It is the first study to look at the effects of those four preventable risk factors on life expectancy in the whole nation...

JDRF, Pfizer, Hadassah Medical and the Hebrew University to Collaborate On Diabetes

The Juvenile Diabetes Research Foundation (JDRF) said that it will begin a diabetes research collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes...